| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/JVI.74.6.2584-2593.2000 |
| P8608 | Fatcat ID | release_3lup35q44rhbxefoudqlw44euu |
| P932 | PMC publication ID | 111746 |
| P698 | PubMed publication ID | 10684272 |
| P2093 | author name string | L Li | |
| B Fisher | |||
| N Bischofberger | |||
| J D Lifson | |||
| D Wodarz | |||
| M A Nowak | |||
| M Piatak | |||
| V M Hirsch | |||
| G Walsh | |||
| B M Flynn | |||
| J L Rossio | |||
| D K Schneider | |||
| R Arnaout | |||
| R F Kiser | |||
| R J Imming | |||
| T L Parks | |||
| V J Coalter | |||
| P2860 | cites work | Viral immune evasion due to persistence of activated T cells without effector function | Q24646943 |
| Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia | Q28254584 | ||
| HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood | Q28257275 | ||
| Interferon-alpha and 3'-azido-3'-deoxythymidine are highly synergistic in mice and prevent viremia after acute retrovirus exposure | Q28330415 | ||
| Vaccination with a live retrovirus: the nature of the protective immune response | Q28335614 | ||
| Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy | Q29615992 | ||
| Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques. | Q33643898 | ||
| Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. | Q33697044 | ||
| Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment | Q33782843 | ||
| CD40 ligand-mediated interactions are involved in the generation of memory CD8(+) cytotoxic T lymphocytes (CTL) but are not required for the maintenance of CTL memory following virus infection | Q33783902 | ||
| Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. | Q33784777 | ||
| Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection | Q77944802 | ||
| Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection. | Q33813926 | ||
| Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation | Q33814150 | ||
| Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection | Q33817504 | ||
| Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment, and prevention | Q34050736 | ||
| Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations | Q34423807 | ||
| 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques | Q35129347 | ||
| Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. | Q35861490 | ||
| Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection | Q35895554 | ||
| Protection against immunopathological consequences of a viral infection by activated but not resting cytotoxic T cells: T cell memory without "memory T cells"? | Q35959154 | ||
| Phenotypic variation in the response to the human immunodeficiency virus among derivatives of the CEM T and WIL-2 B cell lines | Q36355185 | ||
| The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection | Q36548993 | ||
| Protective cellular retroviral immunity requires both CD4+ and CD8+ immune T cells | Q36687914 | ||
| Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy | Q39595379 | ||
| Identification of highly attenuated mutants of simian immunodeficiency virus | Q39642374 | ||
| Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. | Q39877649 | ||
| HIV type 1-specific helper T cells: a critical host defense | Q40850639 | ||
| Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. | Q40994848 | ||
| On T cell memory: arguments for antigen dependence | Q41091839 | ||
| Murine and simian retrovirus models: the threshold hypothesis | Q41179589 | ||
| Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells | Q41305656 | ||
| Immunology and immunity studied with viruses | Q41434540 | ||
| Immunization with whole inactivated vaccine protects from infection by SIV grown in human but not macaque cells | Q41491967 | ||
| Characterization of clones of HIV-1 infected HuT 78 cells defective in gag gene processing and of SIV clones producing large amounts of envelope glycoprotein | Q41751664 | ||
| The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses | Q41870329 | ||
| CD40L-deficient mice show deficits in antiviral immunity and have an impaired memory CD8+ CTL response. | Q41898717 | ||
| Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction | Q44244285 | ||
| CD40 ligand is pivotal to efficient control of virus replication in mice infected with lymphocytic choriomeningitis virus. | Q45753109 | ||
| Protective immunity induced by live attenuated simian immunodeficiency virus | Q45753990 | ||
| Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection | Q45754857 | ||
| Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques | Q45755290 | ||
| Exhaustion of CTL memory and recrudescence of viremia in lymphocytic choriomeningitis virus-infected MHC class II-deficient mice and B cell-deficient mice | Q45768069 | ||
| Chemoprevention of retroviral infection: success is determined by virus inoculum strength and cellular immunity | Q45776852 | ||
| Infectivity of titered doses of simian immunodeficiency virus clone E11S inoculated intravenously into rhesus macaques (Macaca mulatta). | Q45782279 | ||
| New antiretrovirals and new combinations. | Q45999992 | ||
| Immunomodulatory properties of antiviral acyclic nucleotide analogues: cytokine stimulatory and nitric oxide costimulatory effects | Q47937482 | ||
| A functional and kinetic comparison of antiviral effector and memory cytotoxic T lymphocyte populations in vivo and in vitro. | Q52040554 | ||
| Dynamics of cytotoxic T-lymphocyte exhaustion. | Q52247788 | ||
| Control of HIV despite the Discontinuation of Antiretroviral Therapy | Q56851967 | ||
| Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques | Q73379022 | ||
| Antiretroviral agent (R)-9-(2-phosphonomethoxypropyl)adenine stimulates cytokine and nitric oxide production | Q73635253 | ||
| Early postinfection antiviral treatment reduces viral load and prevents CD4+ cell decline in HIV type 2-infected macaques | Q73851290 | ||
| Management of antiretroviral therapy | Q74842321 | ||
| Characterization of HIV-1-specific T-helper cells in acute and chronic infection | Q77323949 | ||
| Immune control of HIV-1 replication | Q77798108 | ||
| P433 | issue | 6 | |
| P921 | main subject | Simian immunodeficiency virus | Q1890246 |
| anti-retroviral agent | Q50430310 | ||
| P304 | page(s) | 2584-2593 | |
| P577 | publication date | 2000-03-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment | |
| P478 | volume | 74 |
| Q77719659 | AIDS vaccine models: challenging challenge viruses |
| Q35003539 | AIDS vaccines and preexposure prophylaxis: is synergy possible? |
| Q34326613 | ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency |
| Q95785042 | An intrinsic way of multiclassification of endogenous psychoses. A follow-through investigation/Budapest 2000/based upon Leonhard's classification |
| Q44282778 | Anti-HIV therapeutic approaches in animal models |
| Q39607060 | Antiretroviral agents restore Mycobacterium-specific T-cell immune responses and facilitate controlling a fatal tuberculosis-like disease in Macaques coinfected with simian immunodeficiency virus and Mycobacterium bovis BCG |
| Q36539952 | Antiviral therapy during primary simian immunodeficiency virus infection fails to prevent acute loss of CD4+ T cells in gut mucosa but enhances their rapid restoration through central memory T cells |
| Q34762295 | Boosting immunity by antiviral drug therapy: a simple relationship among timing, efficacy, and success |
| Q34180174 | Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice |
| Q19028101 | CCL3L1-CCR5 Genotype Improves the Assessment of AIDS Risk in HIV-1-Infected Individuals |
| Q37072697 | CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals |
| Q34142932 | CD8+ and CD20+ lymphocytes cooperate to control acute simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys: modulation by major histocompatibility complex genotype |
| Q37730097 | CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment |
| Q34223069 | Cellular immune responses to HIV. |
| Q36389032 | Characterization of peripheral and mucosal immune responses in rhesus macaques on long-term tenofovir and emtricitabine combination antiretroviral therapy. |
| Q26825814 | Considerations in the development of nonhuman primate models of combination antiretroviral therapy for studies of AIDS virus suppression, residual virus, and curative strategies |
| Q73035497 | Containing HIV after infection |
| Q34465510 | Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particles |
| Q82385263 | DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued |
| Q64377680 | Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses |
| Q36473475 | Early Control of Highly Pathogenic Simian Immunodeficiency Virus/Human Immunodeficiency Virus Chimeric Virus Infections in Rhesus Monkeys Usually Results in Long-Lasting Asymptomatic Clinical Outcomes |
| Q40295877 | Early Initiation of Antiretroviral Therapy Can Functionally Control Productive HIV-1 Infection in Humanized-BLT Mice |
| Q33762877 | Early antibody therapy can induce long-lasting immunity to SHIV |
| Q59355095 | Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound |
| Q36481186 | Ecological and evolutionary principles in immunology |
| Q34348640 | Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection |
| Q45413785 | Effects of monotherapy with (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) on the evolution of a primary Simian immunodeficiency virus (SIV) isolate. |
| Q27021082 | Efficacy of HIV Postexposure Prophylaxis: Systematic Review and Meta-analysis of Nonhuman Primate Studies |
| Q37511699 | Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein |
| Q35947552 | Estimating the infectivity of CCR5-tropic simian immunodeficiency virus SIV(mac251) in the gut. |
| Q36398125 | HIV disease: fallout from a mucosal catastrophe? |
| Q22252422 | HIV infection: first battle decides the war |
| Q36104156 | HIV therapy: managing resistance |
| Q35166836 | HIV vaccines 1983-2003. |
| Q45954015 | HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. |
| Q51637873 | Heterogeneity in chronic myeloid leukaemia dynamics during imatinib treatment: role of immune responses. |
| Q34255654 | Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection |
| Q43522584 | Identification of broadly recognized, T helper 1 lymphocyte epitopes in an equine lentivirus |
| Q34370314 | Immune clearance of highly pathogenic SIV infection |
| Q35023525 | Immune intervention strategies for HIV-1 infection of humans in the SIV macaque model. |
| Q34876070 | Immune reconstitution |
| Q43213534 | Immunity and protection by live attenuated HIV/SIV vaccines |
| Q41982002 | Infection of HIV-specific CD4 T helper cells and the clonal composition of the response |
| Q37248025 | Initiation of antiretroviral therapy 48 hours after infection with simian immunodeficiency virus potently suppresses acute-phase viremia and blocks the massive loss of memory CD4+ T cells but fails to prevent disease |
| Q40173243 | Kinetics of Lymphocyte Proliferation during Primary Immune Response in Macaques Infected with Pathogenic Simian Immunodeficiency Virus SIVmac251: Preliminary Report of the Effect of Early Antiviral Therapy |
| Q39796603 | Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses |
| Q47574091 | Mathematical Models of HIV Latency |
| Q21245370 | Modeling the within-host dynamics of HIV infection |
| Q39604412 | Multiple effector functions mediated by human immunodeficiency virus-specific CD4(+) T-cell clones |
| Q34407781 | Nonhuman primate models for HIV cure research |
| Q38643834 | Of Mice, Macaques, and Men: Broadly Neutralizing Antibody Immunotherapy for HIV-1. |
| Q34071754 | Optimal antiviral switching to minimize resistance risk in HIV therapy |
| Q33299456 | Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings |
| Q73733752 | Prior DNA immunization enhances immune response to dominant and subdominant viral epitopes induced by a fowlpox-based SIVmac vaccine in long-term slow-progressor macaques infected with SIVmac251 |
| Q34712708 | Promises and pitfalls in the reconstitution of immunity in patients who have HIV-1 infection |
| Q76390304 | Prospects for an AIDS vaccine |
| Q33852720 | Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors |
| Q33813173 | Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost |
| Q37273289 | Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection |
| Q35851778 | Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses |
| Q34465037 | Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine. |
| Q33847673 | Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment |
| Q21558500 | Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers |
| Q35752812 | Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection |
| Q35917152 | Structured treatment interruptions in HIV infection: benefit or disappointment? |
| Q34207580 | Structured treatment interruptions to control HIV-1 and limit drug exposure |
| Q38491191 | Success and failure of the cellular immune response against HIV-1. |
| Q51277967 | Sustained and transient oscillations and chaos induced by delayed antiviral immune response in an immunosuppressive infection model. |
| Q44097571 | Systemic vaccination prevents the total destruction of mucosal CD4 T cells during acute SIV challenge |
| Q30386549 | Targeting early infection to prevent HIV-1 mucosal transmission. |
| Q33971030 | The CD4(+) T cell response to HIV-1. |
| Q35200862 | The acute HIV infection: implications for intervention, prevention and development of an effective AIDS vaccine |
| Q45669391 | The impact of early immune destruction on the kinetics of postacute viral replication in rhesus monkey infected with the simian-human immunodeficiency virus 89.6P. |
| Q34632089 | The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? |
| Q55546058 | The race between initial T-helper expansion and virus growth upon HIV infection influences polyclonality of the response and viral set-point. |
| Q35851774 | The roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines |
| Q34143945 | Transient antiretroviral treatment during acute simian immunodeficiency virus infection facilitates long-term control of the virus |
| Q44589651 | Transient early post‐inoculation anti‐retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut‐associated lymphoid tissues in SIVmac239‐infected rhesus macaques, but not resistance to rechallenge |
| Q36228649 | Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge |
| Q58815987 | Vaccination with CTL epitopes that escape: an alternative approach to HIV vaccine development? |
| Q33850355 | Vaccination with attenuated simian immunodeficiency virus by DNA inoculation |
| Q33810277 | Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus |
| Q36539997 | Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery |
| Q33724322 | Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys |
| Q34651604 | Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239 |
| Q34332708 | Vaccines for the prevention of HIV-1 disease |
| Q39605198 | Variability of viral load in plasma of rhesus monkeys inoculated with simian immunodeficiency virus or simian-human immunodeficiency virus: implications for using nonhuman primate AIDS models to test vaccines and therapeutics |
| Q45734459 | Variable fate of virus-specific CD4(+) T cells during primary HIV-1 infection |
| Q34328792 | Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection |
| Q42771066 | Virus dynamics in the presence of synaptic transmission |
Search more.